One emerging approach in cancer treatment including HNSCC involves the use of small molecule kinase inhibitors (smKI) targeting Ataxia telangiectasia mutated (ATM) or Ataxia telangiectasia mutated and Rad3-related (ATR) kinases (10, 11). This evidence concerns the gene ATR and cancer.